

Amendment

In the Claims:

Please cancel claims 5-6, 14-15 and 19-29 without prejudice. Please Amend claim 30 as follows.

1-29. (Canceled)

<sup>1</sup>  
~~30.~~ (Currently Amended) [4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetic acid ~~or a pharmaceutically acceptable derivative thereof.~~

<sup>2</sup>  
~~31.~~ (Previously Presented) A composition comprising the compound according to claim ~~30~~ in admixture with one or more physiologically acceptable carriers or excipients.

<sup>3</sup>  
~~32.~~ (Previously Presented) The composition according to claim <sup>2</sup>~~31~~, further comprising one or more therapeutic agents selected from the group consisting of a cyclooxygenase 2 inhibitor, a 5-lipoxygenase inhibitor, low dose aspirin, non-steroidal anti-inflammatory drugs, a leukotriene receptor antagonist, disease modifying anti-rheumatic drugs, an adenosine 1 agonist, a recombinant human tumor necrosis factor receptor fusion protein, a sodium channel antagonist, an N-methyl D-aspartate antagonist, and a 5HT1 agonist.


<sup>4</sup>  
~~33.~~ (Previously Presented) A method of treating neuropathic pain in a mammal in need thereof comprising administering an effective amount of the compound according to claim ~~30~~.

<sup>5</sup>  
~~34.~~ (Previously Presented) A method of treating colon cancer in a mammal in need thereof comprising administering an effective amount of the compound according to claim ~~30~~.

~~6~~  
~~35.~~ (Previously Presented) A method of treating migraine in a mammal in need thereof comprising administering an effective amount of the compound according to claim ~~30.~~ |

~~7~~  
~~36.~~ (Previously Presented) A method for increasing the latency of HIV infection in a mammal in need thereof comprising administering an effective amount of the compound according to claim ~~30.~~ |

~~8~~  
~~37.~~ (Previously Presented) A process for preparing the compound according to claim ~~30,~~ comprising the step of reducing the compound



with a suitable reducing agent, followed by separation of isomers and deprotection.